Diagnosis (No. of Patients) | Â | Â | Â |
---|---|---|---|
MDS | Â | 31 | Â |
 | RA |  | 5 |
 | RARS |  | 13 |
 | RCMD |  | 1 |
 | RAEB-1 |  | 4 |
 | RAEB-2 |  | 7 |
 | MDS-U |  | 1 |
MDS/MPN | Â | 7 | Â |
 | CMML-1 |  | 2 |
 | CMML-2 |  | 2 |
 | MDS/MPN-U |  | 3 |
PMF | Â | 2 | Â |
sAML | Â | 2 | Â |
Age (years old) | Â | Â | Â |
 | Median (Range) |  | 70 (46-83) |
Sex (No. of Patients) | Â | Â | Â |
 | M |  | 28 |
 | F |  | 14 |
IPSS (No. of Patients) | Â | Â | Â |
 | LOW |  | 12 |
 | INT-1 |  | 11 |
 | INT-2 |  | 7 |
 | HIGH |  | 1 |
 | not indicated |  | 11 |
Duration of MDS (months) | |||
 | Median (Range) |  | 15 (0-118) |
Previous Therapies | |||
 | Yes |  | 27 |
 | No |  | 15 |
Transfusion dependence (No. of Patients) | |||
 | Yes |  | 30 |
 | No |  | 12 |
Neutropenia (< 1.5 × 109/μ) (No. of Patients) | |||
 | Yes |  | 5 |
 | No |  | 37 |
Thrombocytopenia (< 100 × 109) (No. of Patients) | |||
 | Yes |  | 12 |
 | No |  | 30 |
Therapy (No. of Patients) | |||
   LEN (5-10 mg/day) alone |  |  | 30 |
   LEN high dose (50 mg/day) |  |  | 1 |
 | LEN/AZA |  | 11 |
Duration of LEN therapy (months) | |||
 | Median (Range) |  | 5 (0-76) |
Response to therapy (No. of Patients) | |||
 | CR |  | 9 |
 | PR |  | 3 |
 | HI |  | 10 |
 | NR |  | 16 |
 | NE |  | 4 |